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For information regarding this article, E-mail: anniew@usc.edu A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia* receipt of standard treatment, one in three patients experiences persistent bacteremia (PB) in which the growth of bacteria from the bloodstream persists beyond 7 days (3, 4) . PB is significantly associated with metastatic complications, relapse, prolonged hospitalization, and increased mortality (4, 5) . Adding to the challenge are the numerous reports of treatment failure in methicillin-resistant S. aureus (MRSA) associated with the development of resistance to the treatment standard (vancomycin) (6) . To date, multiple studies have assessed both clinical and microbial variables that may be associated with PB (3) (4) (5) . Reduced susceptibility to vancomycin, accessory gene regulator dysfunction, and lack of timely source control have been identified as risk factors of PB (4, 6, 7) . However, studies have reported conflicting results with the risk factors identified so far, suggesting that differential host immune response may contribute to the heterogeneity in outcomes.
Recent studies have pointed to the patient's immune response as a significant predictor of both persistence of infection and outcomes (8) (9) (10) (11) . Specifically in SAB, Rose et al (8) found that those who died had increased interleukin (IL)-10 levels at onset of infection, possibly conferring a state of "immunoparalysis" from an exaggerated anti-inflammatory response. The study did not evaluate the impact of treatment on host innate immune response. Elevated IL-10/tissue necrosis factor (TNF) ratio at 48 hours post infection was predictive of mortality in a cohort of 65 patients with bacterial sepsis; of whom, seven had SA infections (12) . The objective of our study was to establish a quantitative marker of host immune response to SAB that can identify patients at risk of poor outcomes, early during treatment to allow the clinician to make a prompt change in management approach. We assessed host immune response by measuring serum levels of proinflammatory (TNF, IL-6, IL-8, and IL-17A) and anti-inflammatory (IL-10) cytokines at onset of infection and at 72 hours after treatment. We hypothesize that an excess of anti-inflammatory to proinflammatory cytokine ratio early during SAB is predictive of poor outcome.
MATERIALS AND METHODS
This was a prospective observational cohort study conducted at three university-affiliated medical centers (625-bed community, 411-bed academic, and 600-bed county) in Los Angeles County, CA. The study protocol was approved by institutional review boards at each study site. Informed consent was waived as this was an observational study. Adult patients with SAB hospitalized between July 2012 and August 2014 were screened for eligibility. Patients were identified using the microbiology laboratory computer records for the growth of S. aureus from a blood specimen. For patients with multiple admissions during the study period, only the initial admission was included. Patients were excluded if they had polymicrobial growth from blood culture, unavailable medical charts, received less than 48 hours of effective antibiotic therapy, or delayed initiation (> 48 hr) of effective therapy from time of initial positive blood culture.
Bacterial Isolates
S. aureus isolates from blood cultures were collected and stored at -80°C until later testing. Antimicrobial susceptibility testing was performed by using the Vitek System (bioMérieux, Durham, NC) and Etest (bioMérieux, Durham, NC) for vancomycin. Results were interpreted following Clinical and Laboratory Standards Institute guidelines (13) . Bacterial isolates were cultured overnight in tryptic soy broth at 37°C. The staphylococcal cassette chromosome (SCC) mec type was determined on the initial isolate from each patient by polymerase chain reaction assay using previously published methods (14, 15) .
Cytokine Analysis
Plasma or serum samples were collected from specimens drawn for routine labs once physician-ordered tests were completed. Samples were collected at onset of SAB (within 24 hr of the index positive blood culture) and at 72 hours after starting effective antibiotic therapy and stored at -80°C until analysis. Cytokine concentrations were determined by using Luminex multiplex assay according to manufacturer's instructions (Millipore, Billerica, MA) for proinflammatory cytokines: TNF, IL-6, IL-8, and IL-17A and anti-inflammatory cytokine: IL-10. Individual ratio of IL-10 to each proinflammatory mediator was calculated for each patient at both time points. Samples were allowed to thaw to room temperature only once before testing. All assays were performed in duplicate.
Data Collection
Patients' medical records were reviewed for pertinent clinical information: age, gender, comorbid conditions, the presence of hardware, residence before admission, IV drug use history, history of S. aureus infection or vancomycin use (within 6 mo), history of previous hardware infection, admission to the ICU, daily vital signs, clinical response, WBC count, culture and sensitivities, echocardiographic findings, surgical interventions, and infectious disease consultation. In addition, duration of intensive care and hospital stay and 30-day mortality were recorded. Comorbid conditions included diabetes mellitus, cardiovascular disease, renal insufficiency (serum creatinine, > 2 mg/dL or 34.2 mmol/L), requirement for hemodialysis, and immunosuppression (receipt of chemotherapy or other immunosuppressive drugs). The Pitt bacteremia score (PBS), an illness severity scoring system previously validated in SAB (16) , was calculated at onset of bacteremia based on the following variables: temperature, blood pressure, need for mechanical ventilation, cardiac arrest, and mental status. Details of antimicrobial therapy (agent, dose, duration, and serum trough levels for vancomycin) during hospital course were recorded. Study data were managed using the Research Electronic Data Capture (REDCap) software (17) hosted at the University of Southern California. of infection considered low risk were IV catheters, urinary tract infection, ear-nose-larynx, gynecologic, and several manipulation-related sources; intermediate risk were osteoarticular, soft-tissue, and unknown sources; and high risk were endovascular, low respiratory tract, intra-abdominal, and central nervous system foci. Antibiotic therapy was considered effective if sensitivity was documented. Early response was evaluated on day 4 (72-96 hr) after initiation of effective antibiotic therapy. Recurrence was defined as growth of S. aureus from the blood within 30 days of completion of effective antibiotic therapy.
Data Analysis
The primary outcome was response at day 4 after initiation of effective therapy, dichotomized as PB (positive blood culture despite effective treatment) or resolution (partial or complete clinical response with negative blood culture). Clinical response was based on resolution of fever, leukocytosis, local signs of infection, return of abnormal vital signs, and altered mental status to baseline. Secondary outcomes were 30-day all-cause mortality and recurrence of SAB. Day 4 outcome groups were compared on host and microbiologic characteristics, as well as cytokine profile. Univariate analysis was performed using Wilcoxon rank-sum tests or Student t test for continuous data and Fisher exact or chi-square test for categorical data where appropriate. Receiver operating characteristics (ROC) analysis was performed to determine the cytokine cutoff values that maximized sensitivity and specificity in the prediction of PB and 30-day mortality. Multivariate logistic regression analysis was conducted to determine independent predictors of each outcome after controlling for age and gender and adjusting for confounding variables, such as infection source risk category, immunosuppression, and ICU admission. All statistical tests were 2-tailed, and p value of less than 0.05 was considered significant. Statistical analyses were performed using Prism version 4.0 (GraphPad Software, San Diego, CA) or SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS

Study Population
A total of 240 adult hospitalized patients with positive blood cultures for S. aureus were screened. Of those, 196 patients met inclusion criteria. Seventeen patients who received less than 48 hours of effective therapy, five patients who received therapy more than 48 hours after initial positive blood culture, 10 patients who had polymicrobial bacteremia, and 12 patients who had unavailable medical charts were excluded. Study patients had mean (sd) age of 59 (6.6) years; more than half (61%) were men. Nosocomial SAB (onset, > 48 hr after admission) occurred in 14% of patients. PB on day 4 after the start of effective therapy occurred in 24% of patients (47/196). Characteristics of patients were compared between those who had resolving vs PB on day 4 ( Table 1 ). The study groups did not differ in age, gender, comorbid conditions, history of S. aureus infection, previous vancomycin use, or the presence of infected hardware. The most common infection source in the study cohort was skin and soft tissue infection (18%), followed by unknown source (14%), dialysis catheter (13%), line infection (11%), and pneumonia (8%). The majority of patients who died (52%; 101/196) had infection sources associated with intermediate risk of death. Notably, the median PBS, with a possible range of 0-14 points, was low in both groups (1 point); however, twice as many patients with PB required ICU admission during bacteremia (51% vs 28%; p < 0.01). [7/12] ; p = 0.52). Nearly all initial S. aureus isolates had vancomycin minimal inhibitory concentration (MIC) more than 1 µg/mL by Etest (bioMérieux) (44% had 1.5 µg/mL and 41% had 2 µg/mL); none had MIC more than 2 µg/mL.
Pathogen Characteristics
Management of SAB and Outcome
Management of SAB was similar between those who had resolution versus PB on day 4 with respect to time to receipt of effective therapy and hardware removal ( Table 2) . Infected hardware was removed within the first 4 days of onset of bacteremia with a trend toward earlier removal in the resolving group (median, 2 d vs 4 d; p = 0.06). Most patients received vancomycin-containing regimens empirically in both the persistent and resolving groups (70% vs 82%; p = 0.10) ( Table 2 ). Average overall vancomycin trough level was a median of 11.70 versus 11.95 mg/dL (p = 0.32) and did not differ between groups.
Of the 47 patients (24%) in the study cohort who had PB on day 4, 28% died; in contrast, less than 5% died in the resolving group (p < 0.0001) ( Table 2 ). The majority of those who survived in both groups were discharged home (61%, 86/142 vs 53%, 18/34; p = 0.44). Among the survivors, recurrence of SAB within 30 days of completing therapy occurred in eight patients in the resolving group and one in the persistent group.
Host Cytokine Profile and Outcome Analysis
Proinflammatory and anti-inflammatory cytokine levels were higher in all patients at onset of SAB relative to the 72-hour time point post treatment initiation (Fig. 1) . Notably, at initial presentation, the persistent group had higher proinflammatory response with significantly higher median TNF level (44.73 vs 21.68 pg/mL; p < 0.001), IL-6 (139.85 vs 74.22 pg/ mL; p = 0.33), and IL-8 (124.67 vs 47.48 pg/mL; p = 0.028) compared with those with early resolution. Similarly, the persistent group had a 3.5-fold higher anti-inflammatory cytokine level (IL-10) versus the resolving group (median, 104.31 vs 29.72 pg/mL; p < 0.001) at initial presentation. (Fig. 1) As expected, after receipt of 72 hours of effective therapy, both the proinflammatory and anti-inflammatory cytokine levels decreased in both groups, yet all cytokine levels remained significantly higher in the persistent compared with the resolving group (median values): TNF (26.95 vs 18.38 pg/mL; p = 0.016), IL-6 (67.50 vs 21.81 pg/mL; p = 0.005), IL-8 (70.75 vs 27.86 pg/mL; p = 0.002), and IL-10 (30.98 vs 12.6 pg/mL; p < 0.001). IL-17A levels did not significantly differ between the groups at both time points. When the balance of host cytokine response based on IL-10/TNF ratio was examined for individual patients, those with PB at day 4 showed a predominance of anti-inflammatory response (IL-10/TNF ratio: 1.53 vs 0.69; p < 0.001).
Similar findings were observed when host cytokine profile was analyzed in relation to 30-day mortality. Compared with survivors, those who died had a much more robust cytokine storm with higher initial cytokine levels (median values): TNF (65.80 vs 22.60 pg/mL; p < 0.001), IL-8 (130.3 vs 58.50 pg/mL; p = 0.043), and IL-10 (159.50 vs 30.80 pg/mL; p = 0.002). Initial IL-6 (192.70 vs 75.90 pg/mL; p = 0.096) and IL-17A (3.61 vs 3.30 pg/mL; p = 0.55) levels were not significantly different.
Even after 72 hours of effective therapy, those who died continued to have significantly higher proinflammatory and anti-inflammatory levels than survivors: TNF (34.42 vs 18.56 pg/mL; p = 0.002), IL-8 (112.10 vs 31.92 pg/mL; p = 0.002), IL-6 (147.60 vs 22.11 pg/mL; p = 0.002), and IL-10 (109.00 vs 14.81 pg/mL; p < 0.001). Similarly, IL-10/TNF ratio at 72 hours was 4.3-fold higher in the nonsurvivors (3.10 vs 0.70; p < 0.001). Comparing the change in cytokine levels from initial time point to 72 hours after therapy in each patient, those who died versus survivors had a significantly greater decrease in TNF levels (median [interquartile range (IQR)]: 17.55 [1.58-88.21] pg/mL vs 2.47 [-4.65 to 12.02] pg/mL, p = 0.007; percent change: 44% vs 14%, p = 0.015) but lower magnitude of decrease in IL-10 levels (median [IQR]: 30.64 [-79.37 to 111.3] pg/mL vs 12 [0-108.8] pg/mL, p = 0.51; percent change: 31% vs 60%, p = 0.09) resulting in an overall 1% increase in IL-10/TNF ratio versus 50% decrease among survivors.
By univariate logistic regression, all cytokines measured in the study at onset and at 72 hours were analyzed (by themselves and as a ratio to IL-10) in relation to persistence or resolution of bacteremia at day 4 after initiation of effective therapy. IL-10/TNF ratio at 72 hours was found to be most significantly associated with day 4 outcome; the others did not significantly correlate with persistence and thus were not included in the multivariate analysis (IL-10/IL-8 [odds ratio (OR), 1.07 (0.89-1.29); p = 0.48]; IL-10/IL-6 [OR, 0.92 (0.75-1.14); p = 0.45)]; and IL-10/IL-17A [OR, 1 (0.99-1.00); p = 0.87]). ROC analysis was performed to determine the cutoff values for IL-10/TNF ratio after 72 hours of therapy that predicted the development of PB and 30-day mortality. The cutoff values for IL-10/TNF ratio were more than 1.00 (sensitivity, 1-specificity: 0.67, 0.32) for PB and more than 2.56 (sensitivity, 1-specificity: 0.55, 0.11) for 30-day mortality (Fig. 2) . Of note, 42% (66/156) of the study cohort had elevated initial IL-10/TNF levels more than 1.00, but less than half of those (48%, 32/66) had sustained elevation at 72 hours meeting the IL-10/TNF ratio cutoff value (> 1.00) predictive of PB. Conversely, among the 58% (90/156) of the study cohort whose initial IL-10/TNF ratio was below the cutoff value of 1.00 predictive of persistence, five patients had the ratio increase past the cutoff value at 72 hours after treatment was initiated. In addition, the cutoff values for IL-10/TNF ratio were included in a multivariate logistic regression analysis to identify independent predictors of PB and mortality controlling for potential confounders (age, gender, risk of death by source of infection, immunosuppression, and ICU admission) ( Table 3) . Elevated IL-10/TNF ratio at 72 hours of therapy above the cutoff values was the most significant predictor of both PB (OR, 2.98; 95% CI, 1.39-6.39) and mortality (OR, 9.87; 95% CI, 2.64-36.91).
DISCUSSION
SAB presents a significant challenge to clinicians. SAB affects a large population, and persistence of infection despite receipt of effective therapy occurs in 20-40% of patients (18) . Previous studies have identified several microbial and clinical characteristics associated with PB, but such findings are inconsistent (3, (19) (20) (21) . Specifically, some investigators have found that susceptible strains with high vancomycin MIC or heteroresistant vancomycin-intermediate S. aureus phenotype are associated with PB, whereas others did not find these associations (4, 16, 22) . These inconsistent findings point to the need to better characterize the host immune response during infection in order to address the individual heterogeneity in observed outcome.
Our study is the largest study to date examining the relationship between host cytokine response at onset and at 72 hours following initial treatment and outcomes of SAB. Our study findings are consistent with those from a recently published study (8) that showed that elevated IL-10 level at initial presentation was associated with increased mortality. This relationship has been observed with other infections, such as candidemia (23), meningococcal disease (24) , and Bartonella quintana bacteremia (25) in which an initial elevation of IL-10 was found to be associated with poor outcomes. An excess of the anti-inflammatory mediators is thought to result in a state of "immunosuppression" or "immunoparalysis," which thwarts the host's ability to clear the primary infection and leads to the development of secondary infections (26) . In addition, we observed that elevated initial TNF and IL-8 levels were also associated with poor outcomes. We are the first to examine the impact of treatment on host immune response during SAB by investigating changes in cytokine levels at two time points early during the course of disease, at onset, and at 72 hours after initiation of treatment, to allow for a prompt change in management approach if necessary. Our data support the 72-hour time point measurement in that initial cytokine levels, as well as the balance of proinflammatory/anti-inflammatory cytokines, changed in a bidirectional manner by day 4 following initial treatment. In addition, our data provide a biological explanation with respect to host immune response, corroborating earlier findings from our group that lack of early clinical response to treatment assessed at 72 hours is predictive of eventual treatment failure in patients receiving vancomycin therapy for SAB (22) .
Proinflammatory and anti-inflammatory cytokine responses assessed on day 4 were significantly larger in PB versus resolving bacteremia. Specifically, serum levels of TNF, IL-6, IL-8, and IL-10 levels were significantly elevated after 72 hours of therapy in the PB group. IL-17A is an important mediator of inflammation for neutrophil recruitment; however, it did not seem to differ between those with PB versus resolving bacteremia in our population. Previous studies have shown that elevated IL-6 correlated with severity (27) and death (28) in sepsis. However, these studies included patients with a variety of infection types and organisms. Similarly, IL-8 was shown to be significantly elevated in those with severe sepsis and was evaluated for its potential to be used as a clinical marker for sepsis (29) . Although both IL-6 and IL-8 were found to be significantly elevated in our study, IL-10 had the strongest association with the risk of PB and death. More importantly, we found that the ratio of anti-inflammatory to proinflammatory cytokines (IL-10/TNF) at 72 hours signifying an "immunoparalysis" state is the strongest predictor of early response after adjusting for confounding factors. Our findings are consistent with previously published literature that showed that nonsurvivors with severe sepsis due to various infection types had significantly higher IL10/TNF ratio than survivors (12) . This "immunoparalysis" state provides a biological explanation for the poor response observed in the subset of patients with SAB despite receipt of appropriate antimicrobial therapy. As the 72-hour cytokine profile points to the host immune response as a key determinant of eventual outcomes, this time point provides a quantifiable indicator that can help clinicians with treatment decisions early on during the course of therapy to positively affect outcome. The cutoff values determined for IL-10/TNF ratio at 72 hours predictive of PB on day 4 and 30-day mortality are more than 1.00 and more than 2.56, respectively, which should be validated in future studies. This elevation in IL-10/TNF ratio at 72 hours may be a marker indicative of a sustained dysregulated balance in host-specific immune response tipping toward a state of "immunoparalysis" despite effective antibiotic treatment.
Our study has several limitations. Because of its observational design, confounding factors were not matched for and management of infection was at the discretion of the treating physician. It is notable that potential confounders, such as age, SAB source risk, and PBS, were evenly distributed in both persistent and resolving infection groups. We also adjusted for other potential confounding variables, including gender, immunosuppression, and ICU admission in a multivariate regression model; IL-10/TNF ratio at 72 hours was the most significant covariate associated with PB even after adjustment. We acknowledge that a limited panel of cytokines was analyzed, in which the most robust markers were chosen based on previous published work from in vitro, experimental, and human studies. Plans to include a broader panel of cytokines for future investigations are underway.
CONCLUSIONS
SAB is associated with significant resource utilization and mortality. In this study, about 24% of patients with SAB developed PB despite receipt of "effective" therapy selected based on in vitro susceptibility testing. Of those, 50% required ICU admission and 28% died within 30 days of onset. Although multiple factors (i.e., comorbid conditions, source control, and drug dosing) contribute to persistence and poor outcomes, there is a lack of early markers predictive of poor outcome that clinicians can use to guide management approach at present. Here, we have shown promise with the measurement of host cytokine response early during treatment to identify those at risk for infection persistence and death. We focused on the measurement of cytokines for which there are standardized immunoassays currently performed in specialty labs that can be readily incorporated into routine bedside testing. Our results deserve confirmation in prospective studies to validate the cutpoints identified for the immune biomarkers from this study and to examine the effectiveness of immune biomarkerguided management of SAB. Future studies should determine the underlying mechanisms responsible for the dysregulated balance of cytokine response and design a target-specific intervention necessary to affect a positive outcome. 
